×

On probabilistic certification of combined cancer therapies using strongly uncertain models. (English) Zbl 1343.92205

Summary: This paper proposes a general framework for probabilistic certification of cancer therapies. The certification is defined in terms of two key issues which are the tumor contraction and the lower admissible bound on the circulating lymphocytes which is viewed as indicator of the patient health. The certification is viewed as the ability to guarantee with a predefined high probability the success of the therapy over a finite horizon despite of the unavoidable high uncertainties affecting the dynamic model that is used to compute the optimal scheduling of drugs injection. The certification paradigm can be viewed as a tool for tuning the treatment parameters and protocols as well as for getting a rational use of limited or expensive drugs. The proposed framework is illustrated using the specific problem of combined immunotherapy/chemotherapy of cancer.

MSC:

92C50 Medical applications (general)

Software:

ACADO
PDFBibTeX XMLCite
Full Text: DOI arXiv

References:

[1] Alamir, M., Robust feedback design for combined therapy of cancer, Optim. Control Appl. Methods, 35, January (1), 77-88 (2014) · Zbl 1284.93075
[2] Alamir, M.; Chareyron, S., State-constrained optimal control applied to cell-cycle-specific cancer chemotherapy, Optim. Control Appl. Methods, 28, 3, 175-190 (2007)
[4] Alamo, T.; Tempo, R.; Camacho, E. F., Randomized strategies for probabilistic solutions of uncertain feasibility and optimization problems, IEEE Trans. Autom. Control, 54, 11, 2545-2559 (2009) · Zbl 1367.90106
[5] Alamo, T.; Tempo, R.; Luque, A.; Ramirez, D. R., Randomized methods for design of uncertain systems: Sample complexity and sequential algorithms, Automatica, 52, 160-172 (2015) · Zbl 1309.93192
[6] Brannon-Peppas, L.; Blanchette, J. O., Nanoparticle and targeted systems for cancer therapy, Adv. Drug Deliv. Rev., 64, 206-212 (2012)
[7] Bozic, I. et al.,, Evolutionary dynamics of cancer in response to targeted combination therapy, eLife, 1-15 (2011)
[8] Chareyron, S.; Alamir, M., Mixed immunotherapy and chemotherapy of tumorsfeedback design and model updating schemes, J. Theor. Biol., 45, 444-454 (2009) · Zbl 1405.92125
[9] de Pillis, Lisette G.; Gu, Weiqing; Radunskaya, Ami E., Mixed immunotherapy and chemotherapy of tumorsmodeling, applications and biological interpretations, J. Theor. Biol., 238, 4, 841-862 (2006) · Zbl 1445.92135
[10] DePillis, L. G.; Radunskaya, A. E., A mathematical tumor model with immune resistance and drug therapyan optimal control approach, J. Theor. Med., 3, 79-100 (2001) · Zbl 0985.92023
[11] d׳Onofrio, A.; Ledzewicz, U.; Maurer, H.; Schättler, H., On optimal delivery of combination therapy for tumors, Math. Biosci., 222, 1, 13-26 (2009) · Zbl 1176.92033
[12] Ergun, A.; Camphausen, K.; Wein, L. M., Optimal scheduling of radiotherapy and angiogenic inhibitors, Bull. Math. Biol., 65, 3, 407-424 (2003) · Zbl 1334.92196
[13] Gevertz, J., Optimization of vascular-targeting drugs in a computational model of tumor growth, Phys. Rev. E, 85, 4, 041914 (2012)
[14] Hahnfeldt, Philip; Panigrahy, Dipak; Folkman, Judah; Hlatky, Lynn, Tumor development under angiogenic signaling a dynamical theory of tumor growth, treatment response, and postvascular dormancy, Cancer Res., 59, 19, 4770-4775 (1999)
[15] Houska, B.; Ferreau, H. J.; Diehl, M., ACADO Toolkit—an open source framework for automatic control and dynamic optimization, Optim. Control Appl. Methods, 32, 3, 298-312 (2011) · Zbl 1218.49002
[18] Kassara, K.; Moustafid, A., Angiogenesis inhibition and tumor-immune interactions with chemotherapy by a control set-valued method, Math. Biosci., 231, 2, 135-143 (2011) · Zbl 1214.92042
[19] Katouli, A. A.; Komarova, N., The worst drug rule revisistedmathematical modeling of cyclic cancer treatments, Bull. Math. Biol., 73, 549-584 (2011) · Zbl 1226.92037
[20] Kiran, Kanchi Lakshmi; Lakshminarayanan, S., Global sensitivity analysis and model-based reactive scheduling of targeted cancer immunotherapy, Biosystems, 101, 2, 117-126 (2010)
[22] Ledzewicz, U.; Schättler, H., Antiangiogenic therapy in cancer treatment as an optimal control problem, SIAM J. Control Optim., 46, 3, 1052-1079 (2007) · Zbl 1357.49086
[23] Ledzewicz, Urszula; Schättler, Heinz, Optimal and suboptimal protocols for a class of mathematical models of tumor anti-angiogenesis, J. Theor. Biol., 252, 2, 295-312 (2008) · Zbl 1173.49004
[24] Matveev, Alexey S.; Savkin, Andrey V., Application of optimal control theory to analysis of cancer chemotherapy regimens, Syst. Control Lett., 46, 5, 311-321 (2002) · Zbl 1002.92012
[25] Mayne, D. Q.; Rawlings, J. B.; Rao, C. V.; Scokaert, P. O., Constrained model predictive control: stability and optimality, Automatica, 36, 789-814 (2000) · Zbl 0949.93003
[26] Schrama, D.; Feisfeld, R. A.; Becker, J. C., Antibody targeted drugs as cancer therapeutics, Nat. Rev. Drug Discov., 5, 147-159 (2006)
[27] Swan, G. W., General applications of optimal control in cancer chemotherapy, IMA J. Math. Appl. Med. Biol., 5, 303-316 (1988) · Zbl 0678.92003
This reference list is based on information provided by the publisher or from digital mathematics libraries. Its items are heuristically matched to zbMATH identifiers and may contain data conversion errors. In some cases that data have been complemented/enhanced by data from zbMATH Open. This attempts to reflect the references listed in the original paper as accurately as possible without claiming completeness or a perfect matching.